Skip to main content
    P

    PAVmed Inc (PAVM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.47
    -0.28 (-16.00%)

    Market Cap: $13.03M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    PAVmed Inc (PAVM) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    PAVmed (PAVM) has a market cap of $13.03M and an enterprise value of $23.60M. It kept -15847.30% of revenue as net income over the last 12 months. Revenue grew 410.34% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 81.06% above the market cap, as debt exceeds cash.

    Market Cap$13.03M
    Enterprise Value$23.60M
    Latest price (Nov 17, 2026)$1.47

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.91% in the quarter ended Sep 30, 2026.

    Shares Outstanding6.64M
    Shares Change (QoQ)+5.91%

    Valuation Ratios

    Sales and book value multiples are 66.0x and 0.4x. Its year-end P/S ranged from 2.6x to 113.7x from 2022 to 2024.

    P/S Ratio66.0x
    Forward P/S56.1x
    P/B Ratio0.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 84.69% over 52 weeks and trades 46.15% below its 50-day average.

    Beta (1Y)1.09
    52-Week Change-84.69%
    1-Month Change-34.67%
    3-Month Change-71.18%
    6-Month Change-77.03%
    5-Year Change-99.92%
    10-Year Change-99.96%
    Total Return (1Y)-84.69%
    Total Return (3Y CAGR)-75.34%
    Total Return (5Y CAGR)-76.09%
    Return vs SPY (1Y)-98.66%
    Max Drawdown (1Y)-88.89%
    Max Drawdown (3Y)-99.04%
    Sharpe Ratio (1Y)-1.72
    Correlation with SPY (1Y)0.13
    50-Day Average$2.73
    200-Day Average$6.15
    52-Week Range$1.17 to $12.70
    RSI (14 Days)33.5
    Average Volume (20 Days)25.63K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.41x current liabilities, and total debt is 0.52x shareholder equity.

    Current Ratio0.41x
    Quick Ratio0.41x
    Debt / Equity0.52x
    Interest Coverage-5.84x

    Returns and Efficiency

    Return on invested capital is -38.04% over the last 12 months, against a 5-year average of -4.24%.

    Return on Equity (ROE)-85.43%
    Return on Assets (ROA)-66.62%
    Return on Invested Capital (ROIC)-38.04%
    Return on Capital Employed (ROCE)-175.76%
    ROA (5Y Average)-81.75%
    ROIC (5Y Average)-4.24%
    Asset Turnover0.00x
    Receivables Turnover6.30x

    Scores

    PAVM has an Altman Z-Score of -13.12, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-13.12
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $148.00K over the last 12 months.

    Revenue$148.00K
    Revenue Growth (YoY)+410.34%
    Gross Profit-$315.00K
    Operating Income-$28.59M
    Pretax Income-$23.45M
    Net Income-$23.45M
    EBITDA-$19.98M
    EBIT-$20.06M
    Reported EPS (TTM)-$2.97

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 77.96% of the $35.21M in total assets.

    Cash and Equivalents$3.63M
    Total Debt$14.20M
    Net Debt$10.56M
    Net Debt Per Share$1.59
    Working Capital-$14.11M
    Shareholder Equity$27.45M
    Book Value Per Share$3.54
    Total Assets$35.21M
    Total Liabilities$25.08M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $57.00K of capital spending, operating cash flow left -$4.48M of free cash flow.

    Operating Cash Flow-$4.42M
    Capital Expenditures$57.00K
    Free Cash Flow-$4.48M
    FCF Per Share-$0.56
    Depreciation and Amortization$76.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -19314.19%.

    Gross Margin-212.84%
    Operating Margin-19314.19%
    Pretax Margin-15847.30%
    Net Margin-15847.30%
    EBITDA Margin-13500.00%
    EBIT Margin-13551.35%
    FCF Margin-3024.32%

    Dividends and Yields

    PAVM does not pay a dividend. Its free cash flow yield is -45.86%.

    FCF Yield-45.86%
    Buyback Yield-77.88%
    Shareholder Yield-77.88%

    Stock Splits

    The last split was a 1-for-30 reverse split on Jan 2, 2026.

    Last Split DateJan 2, 2026
    Split TypeReverse split
    Split Ratio1:30

    Peer Position

    Against 9 similar companies, PAVM has the highest P/S and the 3rd highest ROIC.

    P/S Ratio66.0x vs 0.6x median
    ROIC-38.04% vs -147.05% median
    Revenue Growth (Trailing 4 Quarters, YoY)+410.34% vs +7.79% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 190.70% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+190.70%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PAVM

    What is PAVM's market cap?

    PAVmed has a market cap of $13.03M. Its enterprise value, which adds debt and subtracts cash, is $23.60M.

    How many shares of PAVM are outstanding?

    PAVmed has 6.64M shares outstanding.

    Does PAVM pay a dividend?

    No. PAVmed does not pay a dividend.

    How much debt does PAVM have?

    PAVmed has $14.20M of total debt and $3.63M of cash and equivalents, a net debt position of $10.56M.